Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

GlobeNewswire March 30, 2023

Poland and U.K. Regulatory Authorities - URPL and MHRA - Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

GlobeNewswire March 29, 2023

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

GlobeNewswire February 21, 2023

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

GlobeNewswire February 15, 2023

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults

GlobeNewswire February 13, 2023

Akari Therapeutics to Present at Biotech Showcase(TM) 2023

GlobeNewswire January 4, 2023

Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

GlobeNewswire December 1, 2022

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

GlobeNewswire November 22, 2022

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

GlobeNewswire November 10, 2022

Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 9, 2022

Sidoti's November Micro-Cap Virtual Conference

Accesswire November 8, 2022

Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer

GlobeNewswire November 8, 2022

Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference

GlobeNewswire October 31, 2022

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

GlobeNewswire October 28, 2022

Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

GlobeNewswire September 27, 2022

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

GlobeNewswire September 22, 2022

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

GlobeNewswire September 12, 2022

Akari Therapeutics Narrows Pipeline Focus

GlobeNewswire August 1, 2022

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

GlobeNewswire July 28, 2022

Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

GlobeNewswire July 20, 2022